Processing
Processing. Please wait...

BIOLINE insider: Kinneret Savitsky

 
 All Insiders  
 
Summary
Recomendation
   Summary
   Leaders
   Widgets

CEO, Director

Dr. Kinneret Savitsky serves as Chief Executive Officer and Director at BioLine Rx Ltd since January 2010. Prior to that she was General Manager of BioLine Innovations Jerusalem Ltd. since 2004. Dr. Savitsky was formerly Vice President Biology Research and Development at Compugen a biotechnology company. She joined Compugen in 1997 as Senior Scientist in Compugen newly founded laboratory and led the company shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen drug candidate identification and development as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers
Age: 46  CEO Since 2010      
972 2 548 9100  http://www.biolinerx.com

Other Appointments

BioLineRx LtdBLNEFUnited States OTCCEO
BioLineRx LtdBLRXUnited States NasdaqCEO
BIOLINE RXBLRXIsrael Tel AvivCEO
Kinneret Savitsky EducationSavitsky has a BS degree in Biology from The Hebrew University of Jerusalem, MS degree in Human Genetics and a PhD, with distinction, in the Department of Human Genetics, both from the TelAviv University.

Management Efficency

The company has return on total asset (ROA) of (39.95) % which means that it has lost $39.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (77.4) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 44.85 K in total debt. BIOLINE RX LTD has Current Ratio of 3.83 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Kinneret Savitsky Ph.D., 44Chief Exec. Officer327.00KN/AMr. Philip A. Serlin CPA, MBA, 51Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Member of Investment Monitoring Committee271.00KN/AProf. Moshe Phillip M.D., 57VP of Medical Affairs, Sr. Clinical Advisor and Member of Scientific Advisory Board291.00KN/ADr. Leah Klapper Ph.D., 47Gen. Mang. of BioLine Innovations Jerusalem237.00KN/A Raziel Fried, Treasurer and Member of Investment Monitoring CommitteeN/AN/ABIOLINE RX LTD [BLNEF] is traded on OTC Market in USA. It is located in , except where noted. and employs 52 people.

Filter other executives

Tenure
Industry  
Click to run this filter
 
Filter Other Insiders
 

Showing few of many executives

CEO Since

Michael CorbatCitigroup Inc
2012
Timothy MayopoulosFederal National Mortgage Assoc
2012
Soeren SkouAP M
2012
Judith VardiTEVA PHARMA IND
2012
Francisco SilvaCitigroup Inc
N/A
Eliyahu CohenBK HAPOALIM
2011
Carlo NotaristefaniTEVA PHARMA IND
2012
Tsahi CohenBK HAPOALIM
2012
Sigurdur OlafssonTEVA PHARMA IND
2014
Erez VigodmanTEVA PHARMA IND
2014
Shimon GalBK HAPOALIM
2013
Anat LevinBK HAPOALIM
2010
Morten EngelstoftAP M
2014
Kim FejferAP M
2011
Timothy MayopoulosFED NATL MTG PFD I
2012
James CowlesCitigroup Inc
2013
William MillsCitigroup Inc
2013
Ari PintoBK HAPOALIM
2013
Avraham KochvaBK HAPOALIM
2014
Ron WekslerBK HAPOALIM
2013
Jakob ThomasenAP M
2009
SymbolBLNEF
NameBIOLINE RX LTD
InstrumentUSA Stock
Risk-adjusted AdviceNot Rated Unknown Real Value
ExchangeOTC Market
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BIOLINE RX LTD to your portfolio

BIOLINE RX LTD Leadership

Jacob Friedman, Director, MBA
Nurit Benjamini, Director, MBA
Raphael Hofstein, Director
Kinneret Savitsky, CEO
Aharon Schwartz, Chairman
Philip Serlin, COO
Moshe Phillip, President, Ph.D
Michael Anghel, Director, MBA
Leah Klapper, Executive
David Malek, President
Avraham Molcho, Director, MBA
Sandra Panem, Director, Ph.D

Stock Performance

Shares Outstanding150.64 M